IDF2022-0414 iGlarLixi Provides a Higher Derived Time-in-Range vs Insulin Glargine or Lixisenatide in Asian Pacific People with T2D

Autor:	X. Guo, W. Yang, J. Zhang, X. Dong, M. Liu, S. u, F. Lauand, L. Li, E. Souhami
Rok vydání:	2023
Předmět:	Endocrinology Endocrinology Diabetes and Metabolism Internal Medicine General Medicine
Zdroj:	Diabetes Research and Clinical Practice. 197:110307
ISSN:	0168-8227
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0c8cf9c390ffc42e72d11ce9b71dea4a https://doi.org/10.1016/j.diabres.2023.110307 Zobrazit plný text záznamu Full Text from ScienceDirect